Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05287451 · ClinicalTrials.gov registry record · NA
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
A NA study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 9
- Study locations
NCT05287451: Recruiting NA study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by M.D. Anderson Cancer Center.
NCT05287451 is a NA study of Ovarian Cancer and Fallopian Tube Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (86% lower). The trial reports 9 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05287451, a NA study of Ovarian Cancer and Fallopian Tube Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
Conditions Studied
Interventions
- OTHER RIsk-Reducing Salpingectomy (RRS)
- OTHER Risk-Reducing Oophorectomy-RRO
- OTHER Risk-Reducing Salpingo-Oophorectomy-RRSO
Study Locations (9)
New York
- Mount Sinai Health System - New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- Lyndon Baines Johnson General - Houston
- M D Anderson Cancer Center - Houston
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester
Missouri
- WU St Louis - St Louis
Pennsylvania
- University of Pennsylvania - Philadelphia
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-05-10 |
| Est. Completion | 2026-12-26 |
| Phase | NA |
What NCT05287451 shows while recruiting
NCT05287451 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which RIsk-Reducing Salpingectomy (RRS) is the first listed.
NCT05287451 lists 9 locations in 7 states (New York, Texas, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT05287451 about?
NCT05287451 is a clinical study titled "Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study". This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
What is the current status of trial NCT05287451?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-05-10. Estimated completion is 2026-12-26.
What conditions does trial NCT05287451 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer.
What interventions are being tested in trial NCT05287451?
The interventions under investigation include: RIsk-Reducing Salpingectomy (RRS) (OTHER), Risk-Reducing Oophorectomy-RRO (OTHER), Risk-Reducing Salpingo-Oophorectomy-RRSO (OTHER).
Who is sponsoring clinical trial NCT05287451?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05287451 being conducted?
This trial has 9 study locations across Massachusetts, Minnesota, Missouri, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05287451's enrollment target sits among peer trials
100 146th of 322 higher than 172 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
RECRUITING · NA
-
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
RECRUITING · NA
-
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI